DA
KRTX

Duality Advisers’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Duality Advisers’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,880
Closed -$656K – 780
2023
Q3 		$656K Buy
+3,880
New +$730K 0.08% 372
2023
Q2 		– Sell
-11,169
Closed -$2.03M – 774
2023
Q1 		$2.03M Sell
11,169
-2,781
-20% -$532K 0.23% 161
2022
Q4 		$2.74M Buy
13,950
+1,745
+14% +$374K 0.31% 97
2022
Q3 		$2.75M Buy
+12,205
New +$2.47M 0.3% 126

Other funds holding KRTX

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Duality Advisers's KRTX Position: Q4 2023 in Review

Duality Advisers sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023, closing a stake of 3,880 shares — an estimated $656K sold.

Duality Advisers first reported a position in KRTX in Q3 2022 and held it in 4 quarters. The position peaked at $2.75M in Q3 2022. 328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

  • Duality Advisers reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Duality Advisers sold 3,880 Karuna Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $656K.
  • Duality Advisers first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Duality Advisers's Karuna Therapeutics, Inc. Common Stock position peaked at $2.75M in Q3 2022.
  • 328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Duality Advisers's 13F filing for Q4 2023, filed 1 Feb 2024.